WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III

Inclusion Criteria

DISEASE CHARACTERISTICS: Pathological stage III/IV endometrial carcinoma of any histology
(including clear cell and serous papillary carcinomas) The following extent of disease
eligible: Positive adnexa Tumor invading the serosa Positive pelvic nodes Positive
para-aortic nodes Involvement of the bowel mucosa Intra-abdominal metastases Positive
pelvic washings Vaginal involvement within the radiotherapy field Hysterectomy and
bilateral salpingo-oophorectomy (BSO) required with residual tumor not greater than 2 cm
at any site Selective pelvic and para-aortic lymph node sampling optional for patients
with stage III/IV disease by other criteria If para-aortic nodes are positive, scalene
nodes must be negative on biopsy and chest CT must be negative for intrathoracic disease
The following disease conditions exclude: Parenchymal liver metastasis Lung metastasis
Positive inguinal nodes Positive scalene nodes Recurrent disease Protocol therapy must
begin within 8 weeks after surgery

PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-3 Hematopoietic: WBC
at least 3,000/mm3 Absolute granulocyte count at least 1,500/mm3 Platelet count at least
100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal AST no greater than 3
times normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: Left ventricular
ejection fraction normal Other: No past or concomitant malignancy other than
nonmelanomatous skin cancer

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
prior chemotherapy Endocrine therapy: Prior progestational agents allowed No other prior
endocrine therapy Radiotherapy: No prior pelvic or abdominal radiotherapy Surgery:
Hysterectomy and BSO required Pelvic and para-aortic lymph node sampling optional (see
Disease Characteristics)